These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15255205)

  • 1. Genetic antiviral program against hepatitis C virus.
    Sivov IG; Samokhvalov EI; Knyazhev VA
    Dokl Biochem Biophys; 2003; 392():288-91. PubMed ID: 15255205
    [No Abstract]   [Full Text] [Related]  

  • 2. [Different effect of interferon on hepatitis C virus genomes using CAT expression system].
    Yanagi M; Kaneko S; Unoura M; Kobayashi K
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):936-43. PubMed ID: 7563905
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay.
    Seki M; Honda Y
    J Biochem; 1995 Dec; 118(6):1199-204. PubMed ID: 8720135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Form confers function: Case of the 3'X region of the hepatitis C virus genome.
    Dutkiewicz M; Ciesiołka J
    World J Gastroenterol; 2018 Aug; 24(30):3374-3383. PubMed ID: 30122877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.
    Wang W; Hakim MS; Nair VP; de Ruiter PE; Huang F; Sprengers D; Van Der Laan LJ; Peppelenbosch MP; Surjit M; Pan Q
    Gastroenterology; 2016 Dec; 151(6):1251-1253. PubMed ID: 27815000
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiviral genetic program is a new type of DNA vaccine.
    Sivov IG; Sobolev A; Samokhvalov EI; Sergienko VI
    Dokl Biochem Biophys; 2001; 377():137-40. PubMed ID: 11712146
    [No Abstract]   [Full Text] [Related]  

  • 9. The hepatitis C virus internal ribosome-entry site: a new target for antiviral research.
    Gallego J; Varani G
    Biochem Soc Trans; 2002 Apr; 30(2):140-5. PubMed ID: 12023841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs.
    Krönke J; Kittler R; Buchholz F; Windisch MP; Pietschmann T; Bartenschlager R; Frese M
    J Virol; 2004 Apr; 78(7):3436-46. PubMed ID: 15016866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
    Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
    Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for chronic hepatitis C.
    van Soest H; van Hattum J
    Adv Exp Med Biol; 2003; 531():219-26. PubMed ID: 12916794
    [No Abstract]   [Full Text] [Related]  

  • 13. Internal initiation of translation efficiency in different hepatitis C genotypes isolated from interferon treated patients.
    Sáiz JC; López de Quinto S; Ibarrola N; López-Labrador FX; Sánchez-Tapias JM; Rodés J; Martínez-Salas E
    Arch Virol; 1999; 144(2):215-29. PubMed ID: 10470249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model.
    Kim M; Shin D; Kim SI; Park M
    Virus Res; 2006 Dec; 122(1-2):1-10. PubMed ID: 16979254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.
    Thelu MA; Drouet E; Hilleret MN; Zarski JP
    J Med Virol; 2004 Mar; 72(3):396-405. PubMed ID: 14748063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.
    Contreras AM; Hiasa Y; He W; Terella A; Schmidt EV; Chung RT
    J Virol; 2002 Sep; 76(17):8505-17. PubMed ID: 12163570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of an antisense reverse-transcriptase-polymerase chain reaction primer efficient for all hepatitis C virus genotypes: comparison of its performance vs a commercial primer.
    Gonzalez-Perez I; Vina-Rodriguez A; Cayarga AA; Rosa IG; González YJ
    Anal Biochem; 2003 Apr; 315(2):281-4. PubMed ID: 12689840
    [No Abstract]   [Full Text] [Related]  

  • 18. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.
    Ye J; Wang C; Sumpter R; Brown MS; Goldstein JL; Gale M
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15865-70. PubMed ID: 14668447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel sequence found at the 3' terminus of hepatitis C virus genome.
    Tanaka T; Kato N; Cho MJ; Shimotohno K
    Biochem Biophys Res Commun; 1995 Oct; 215(2):744-9. PubMed ID: 7488017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.